We undertake no buy tramadol cash on obligation to publicly update any forward- hydrocodone tannate looking statements, whether as a result of new information, future events or otherwise Document milestones After we divested our injectables business in 2009-10, most industry observers became wary of our growth agenda. Walked a new path that strengthened the organisation, invested in sustainable growth and resolved to enhance shareholder wealth.
In 2010-11, we grew our business and profits in a significant way. The big message which we wish to send out is: Orchid is 'aiming higher'. *Includes profit from the sale of our injectable business Rs 159 crore Profit after tax in 2010-11 from Rs 331 crore* in 2009-10 Earnings per share in 2010-11 compared with Rs 47.04* in 2009-10 Book value per share in 2010-11 as against Rs 139.07 in 2009-10 Rs 2Z:64 We improved our 2010-11 performance in a significant way. Rs 1,663 crore Topline increased in 2010-11 from Rs 1,250 crore in 2009-10 Rs 418 crore EBIDTA in 2010-11 against hydrocodone tannate Rs 852 crore* in 2009-10 Rs 160.99 We tightened our operations. 105 days Receivables cycle (hydrocodone tannate March 31, 2011) 126 days Inventory cycle (March 31, 2011) Net debt equity ratio (March 31, 2011) 1.44 Vision and values .V.
> Innovation Excellence Corporate social responsibility Orchid Chemicals & Pharmaceuticals Ltd: Dream.
•A US$ 400 million pharmaceutical company that caters to business opportunities across the value chain from discovery to delivery, with established credentials in research, manufacturing and marketing. •A globally recognised player with a footprint across more than 70 nations through front-end marketing, alliances and partnerships with reputed global players. Promoters' holding 30.5% March 31, 2011 •A product basket encompassing multiple therapeutic segments hydrocodone tannate namely anti-infectives (oral and sterile), antiinflammatory, central nervous system (CNS), cardio vascular system (CVS) and nutraceutical products. •Corporate headquarters in Chennai with two active pharmaceutical ingredients (API) manufacturing sites (Chennai and Aurangabad), three formulation sites (Chennai), two R&D campuses (Chennai) and one API unit in China (joint venture). Foreign institutional holding 13.45% March 31, 2011 • State-of-the-art manufacturing facilities in compliance with cGMP, cGLP, ISO and OHSAS guidelines; approved by global regulatory authorities such as US FDA, UK MHRA, EDQM, PMDA, hydrocodone tannate DMA, MCC and TGA, reflecting a compliance css order phentermine without prescription with stringent international standards; R&D units are in compliance with the National GLP guidelines. Team size 4,500 March 31, 2011 Capital employed RS 3,174 March 31, 2011 crore crore Market capitalisation RS 2,118 March 31, 2011 .V. > A synopsis of 2010-11 Filings/approvals •Received approval for Meropenem from the US FDA and European regulatory authorities; received approval for Imipenem from the European regulatory authorities •Settled two Para IV-FTF new tramadol tramadol hcl (First-to-File) filings with innovator companies, enabling us to launch the products in the coming years •Filed eight ANDAs (Abbreviated New Drug Applications) with the US regulatory authorities and two Marketing Authorisations in the European market •Received US FDA approvals for five formulations (four tentative and one final) and European approvals for six formulations Business volumes •Commenced supplies of Carbapenem APIs to Hospira •Increased supply of API to Europe based on new supply arrangements •Entered into a long-term contract with a large Japanese pharmaceutical company for the supply of a cephalosporin API Growth initiatives •Acquired Karalex Pharma LLC.
Herbs that mimic hydrocodone
Pharmacy buy tramadol
Buy xanax online in
Ethex oxycodone is poor